<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="jvim70006" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Vet Intern Med</journal-id><journal-id journal-id-type="iso-abbrev">J Vet Intern Med</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1939-1676</journal-id><journal-id journal-id-type="publisher-id">JVIM</journal-id><journal-title-group><journal-title>Journal of Veterinary Internal Medicine</journal-title></journal-title-group><issn pub-type="ppub">0891-6640</issn><issn pub-type="epub">1939-1676</issn><publisher><publisher-name>John Wiley &#x00026; Sons, Inc.</publisher-name><publisher-loc>Hoboken, USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11864850</article-id><article-id pub-id-type="doi">10.1111/jvim.70006</article-id><article-id pub-id-type="publisher-id">JVIM70006</article-id><article-id pub-id-type="other">JVIM-24-428.R3</article-id><article-categories><subj-group subj-group-type="overline"><subject>Standard Article</subject></subj-group><subj-group subj-group-type="heading"><subject>STANDARD ARTICLE</subject><subj-group subj-group-type="heading"><subject>Small Animal Internal Medicine Nephrology/Urology</subject></subj-group></subj-group></article-categories><title-group><article-title>Long&#x02010;Term Outcomes After Prophylactic Infusion of&#x000a0;2% Tetrasodium Ethylenediaminetetraacetic Acid in 95&#x000a0;Subcutaneous Ureteral Bypass Devices in 66 Cats With&#x000a0;Benign Ureteral Obstructions</article-title></title-group><contrib-group><contrib id="jvim70006-cr-0001" contrib-type="author" corresp="yes"><name><surname>Berent</surname><given-names>Allyson</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-1628-4633</contrib-id><xref rid="jvim70006-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>allyson.berent@gmail.com</email></address></contrib><contrib id="jvim70006-cr-0002" contrib-type="author"><name><surname>Weisse</surname><given-names>Chick</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5202-9962</contrib-id><xref rid="jvim70006-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jvim70006-cr-0003" contrib-type="author"><name><surname>Milligan</surname><given-names>Melissa</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6348-2583</contrib-id><xref rid="jvim70006-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jvim70006-cr-0004" contrib-type="author"><name><surname>Mejia</surname><given-names>Jessica</given-names></name><xref rid="jvim70006-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jvim70006-cr-0005" contrib-type="author"><name><surname>Woods</surname><given-names>Sarah</given-names></name><xref rid="jvim70006-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jvim70006-cr-0006" contrib-type="author"><name><surname>Lamb</surname><given-names>Ken</given-names></name><xref rid="jvim70006-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="jvim70006-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>The Animal Medical Center</institution>
<city>New York</city>
<named-content content-type="country-part">New York</named-content>
<country country="US">USA</country>
</aff><aff id="jvim70006-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Lamb Consulting</institution>
<city>St. Paul</city>
<named-content content-type="country-part">Minnesota</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Allyson Berent (<email>allyson.berent@gmail.com</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><season>Mar-Apr</season><year>2025</year></pub-date><volume>39</volume><issue seq="317">2</issue><issue-id pub-id-type="doi">10.1111/jvim.v39.2</issue-id><elocation-id>e70006</elocation-id><history>
<date date-type="rev-recd"><day>30</day><month>12</month><year>2024</year></date>
<date date-type="received"><day>24</day><month>9</month><year>2024</year></date>
<date date-type="accepted"><day>14</day><month>1</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 American College of Veterinary Internal Medicine--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Journal of Veterinary Internal Medicine</italic> published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JVIM-39-e70006.pdf"/><abstract><title>ABSTRACT</title><sec id="jvim70006-sec-0001"><title>Background</title><p>The use of subcutaneous ureteral bypass device(s) (SUB) for the treatment of benign ureteral obstructions (BUO) in cats has become more routine in veterinary practices. Device mineralization and chronic urinary tract infections (UTI) are the most reported long&#x02010;term complications.</p></sec><sec id="jvim70006-sec-0002"><title>Hypothesis/Objective</title><p>To evaluate the occurrence of mineralization, bacteriuria, and chronic infections in cats after SUB placement, where 2% tetrasodium ethylenediaminetetraacetic acid (tEDTA) was infused during standard SUB flushing when compared to a historical control group where sterile saline was used for flushing. The hypothesis is that tEDTA will decrease the rate of mineralization occlusions and infections of SUB devices without increasing other complications.</p></sec><sec id="jvim70006-sec-0003"><title>Animals</title><p>Ninety&#x02010;five SUBs (39 unilateral; 28 bilateral) in 66 cats.</p></sec><sec id="jvim70006-sec-0004"><title>Methods</title><p>Retrospective study; Medical records from all cats that had &#x0003e;&#x02009;180&#x02010;day follow&#x02010;up after undergoing SUB device placement were evaluated. Group 1 consisted of cats flushed routinely with saline only, Group 2 with saline and then switched to 2% tEDTA during their follow&#x02010;up period, and Group 3 with 2% tEDTA only.</p></sec><sec id="jvim70006-sec-0005"><title>Results</title><p>Device mineralization was documented in 9/28 (32%), 8/16 (50%), and 10/51 (19%) SUB devices in Groups 1, 2, and 3, respectively (<italic toggle="no">p</italic>&#x02009;=&#x02009;0.025). Exchange was needed from re&#x02010;obstruction in 4/28 (14%), 5/16 (31%) and 3/51 (6%), respectively (<italic toggle="no">p</italic>&#x02009;=&#x02009;0.016). Chronic UTI occurred in 7/21 (33%), 4/12 (33%), and 1/33 (3%) of cats, respectively (<italic toggle="no">p</italic>&#x02009;=&#x02009;0.004). UTI at the time of surgery was associated with the development of a chronic UTI (<italic toggle="no">p</italic>&#x02009;=&#x02009;0.01).</p></sec><sec id="jvim70006-sec-0006"><title>Conclusions/Clinical Importance</title><p>Prophylactic use of 2% tEDTA might be helpful in reducing frequency of long&#x02010;term SUB device complications and could be considered as part of the long term management plan.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jvim70006-kwd-0001">biofilm</kwd><kwd id="jvim70006-kwd-0002">device</kwd><kwd id="jvim70006-kwd-0003">encrustation</kwd><kwd id="jvim70006-kwd-0004">mineralization</kwd><kwd id="jvim70006-kwd-0005">SUB</kwd><kwd id="jvim70006-kwd-0006">ureterolithiasis</kwd></kwd-group><counts><fig-count count="0"/><table-count count="5"/><page-count count="9"/><word-count count="6800"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March/April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:26.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="jvim70006-ntgp-0001"><fn fn-type="funding" id="jvim70006-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn></fn-group></notes></front><body id="jvim70006-body-0001"><def-list list-content="abbreviations" id="jvim70006-dl-0001"><title>Abbreviations</title><def-item><term id="jvim70006-li-0001">ABU</term><def id="jvim70006-li-0002"><p>asymptomatic bacteriuria</p></def></def-item><def-item><term id="jvim70006-li-0003">BUN</term><def id="jvim70006-li-0004"><p>blood urea nitrogen</p></def></def-item><def-item><term id="jvim70006-li-0005">BUO</term><def id="jvim70006-li-0006"><p>benign ureteral obstruction</p></def></def-item><def-item><term id="jvim70006-li-0007">CKD</term><def id="jvim70006-li-0008"><p>chronic kidney disease</p></def></def-item><def-item><term id="jvim70006-li-0009">SUB</term><def id="jvim70006-li-0010"><p>subcutaneous ureteral bypass device</p></def></def-item><def-item><term id="jvim70006-li-0011">tEDTA</term><def id="jvim70006-li-0012"><p>2% tetrasodium ethylenediaminetetraacetic acid</p></def></def-item><def-item><term id="jvim70006-li-0013">UCS</term><def id="jvim70006-li-0014"><p>urine culture and sensitivity</p></def></def-item><def-item><term id="jvim70006-li-0015">UTI</term><def id="jvim70006-li-0016"><p>urinary tract infection</p></def></def-item></def-list><sec id="jvim70006-sec-0007"><label>1</label><title>Introduction</title><p>The use of a subcutaneous ureteral bypass device (SUB)<xref rid="jvim70006-note-0003" ref-type="fn">
<sup>1</sup>
</xref> for the treatment of BUOs has been reported by numerous groups, with the largest series in 134 cats showing good to excellent outcomes [<xref rid="jvim70006-bib-0001" ref-type="bibr">1</xref>, <xref rid="jvim70006-bib-0002" ref-type="bibr">2</xref>, <xref rid="jvim70006-bib-0003" ref-type="bibr">3</xref>, <xref rid="jvim70006-bib-0004" ref-type="bibr">4</xref>, <xref rid="jvim70006-bib-0005" ref-type="bibr">5</xref>, <xref rid="jvim70006-bib-0006" ref-type="bibr">6</xref>, <xref rid="jvim70006-bib-0007" ref-type="bibr">7</xref>]. In the authors' practice, this device has essentially replaced traditional surgery and ureteral stenting for the treatment of ureteral obstructions in cats, regardless of etiology, because of lower morbidity and mortality rates [<xref rid="jvim70006-bib-0001" ref-type="bibr">1</xref>, <xref rid="jvim70006-bib-0002" ref-type="bibr">2</xref>, <xref rid="jvim70006-bib-0003" ref-type="bibr">3</xref>, <xref rid="jvim70006-bib-0004" ref-type="bibr">4</xref>, <xref rid="jvim70006-bib-0005" ref-type="bibr">5</xref>, <xref rid="jvim70006-bib-0006" ref-type="bibr">6</xref>, <xref rid="jvim70006-bib-0007" ref-type="bibr">7</xref>, <xref rid="jvim70006-bib-0008" ref-type="bibr">8</xref>, <xref rid="jvim70006-bib-0009" ref-type="bibr">9</xref>, <xref rid="jvim70006-bib-0010" ref-type="bibr">10</xref>, <xref rid="jvim70006-bib-0011" ref-type="bibr">11</xref>, <xref rid="jvim70006-bib-0012" ref-type="bibr">12</xref>, <xref rid="jvim70006-bib-0013" ref-type="bibr">13</xref>, <xref rid="jvim70006-bib-0014" ref-type="bibr">14</xref>]. Over the past decade, the use of the SUB has become the standard of care for many institutions globally for the treatment of BUO [<xref rid="jvim70006-bib-0001" ref-type="bibr">1</xref>, <xref rid="jvim70006-bib-0002" ref-type="bibr">2</xref>, <xref rid="jvim70006-bib-0003" ref-type="bibr">3</xref>, <xref rid="jvim70006-bib-0004" ref-type="bibr">4</xref>, <xref rid="jvim70006-bib-0005" ref-type="bibr">5</xref>, <xref rid="jvim70006-bib-0006" ref-type="bibr">6</xref>, <xref rid="jvim70006-bib-0007" ref-type="bibr">7</xref>, <xref rid="jvim70006-bib-0009" ref-type="bibr">9</xref>]. This trend is likely due to ease of placement regardless of the underlying etiology or location of the obstructive lesion, generally resulting in shorter surgical times, lower re&#x02010;obstruction rates, and fewer perioperative complications, with overall improved morbidity and mortality rates compared to traditional surgery [<xref rid="jvim70006-bib-0008" ref-type="bibr">8</xref>, <xref rid="jvim70006-bib-0010" ref-type="bibr">10</xref>, <xref rid="jvim70006-bib-0011" ref-type="bibr">11</xref>, <xref rid="jvim70006-bib-0012" ref-type="bibr">12</xref>, <xref rid="jvim70006-bib-0013" ref-type="bibr">13</xref>, <xref rid="jvim70006-bib-0014" ref-type="bibr">14</xref>].</p><p>Additionally, SUBs can be successfully used for nearly all obstructive etiologies including ureterolithiasis, ureteral strictures, obstructive neoplasia, obstructive pyonephrosis, and dried solidified blood stones, where traditional surgical approaches can be incredibly challenging and might not be possible [<xref rid="jvim70006-bib-0001" ref-type="bibr">1</xref>, <xref rid="jvim70006-bib-0003" ref-type="bibr">3</xref>, <xref rid="jvim70006-bib-0006" ref-type="bibr">6</xref>, <xref rid="jvim70006-bib-0015" ref-type="bibr">15</xref>]. The SUB has also generally replaced the use of ureteral stents in cats globally because of the lower incidence of stent&#x02010;associated dysuria and the ease of SUB placement [<xref rid="jvim70006-bib-0008" ref-type="bibr">8</xref>, <xref rid="jvim70006-bib-0010" ref-type="bibr">10</xref>, <xref rid="jvim70006-bib-0011" ref-type="bibr">11</xref>, <xref rid="jvim70006-bib-0012" ref-type="bibr">12</xref>]. Despite the SUB improving many of the outcomes, complications such as chronic mineralization (24%), the need for device exchange (13%), and the development of chronic infections (8%) are reported [<xref rid="jvim70006-bib-0001" ref-type="bibr">1</xref>].</p><p>After SUB placement, an ultrasound&#x02010;guided flush of the device is routinely recommended [<xref rid="jvim70006-bib-0001" ref-type="bibr">1</xref>]. Since mid&#x02010;2017, instillation of 2&#x02009;mL of 2% tEDTA<xref rid="jvim70006-note-0004" ref-type="fn">
<sup>2</sup>
</xref> solution (tEDTA) into the device has been standard in the authors' practice (Figure&#x000a0;<xref rid="jvim70006-supitem-0001" ref-type="supplementary-material">S1</xref>). The tEDTA is a chelating agent that complexes with cations (e.g., calcium). In the literature, irrigation with tEDTA achieved complete dissolution of stones in 145/260 cases, while partial dissolution was seen in 113 cases&#x000a0;[<xref rid="jvim70006-bib-0016" ref-type="bibr">16</xref>]. tEDTA&#x02010;treated&#x02010;catheters have significantly lower rates of encrustation compared to controls [<xref rid="jvim70006-bib-0017" ref-type="bibr">17</xref>], and tEDTA can demineralize occluded SUBs [<xref rid="jvim70006-bib-0018" ref-type="bibr">18</xref>, <xref rid="jvim70006-bib-0019" ref-type="bibr">19</xref>]. This has been met with success in 8/8 cases reported [<xref rid="jvim70006-bib-0018" ref-type="bibr">18</xref>].</p><p>The objective of this study was to evaluate the incidence of mineralization, infections, dysuria, and azotemia when tEDTA was routinely infused into each SUB when compared to a saline infusion control group. The hypothesis to be tested is that tEDTA decreases the rate of mineralization and infections without worsening dysuria or azotemia in cats when compared to saline.</p></sec><sec sec-type="materials-and-methods" id="jvim70006-sec-0008"><label>2</label><title>Materials and Methods</title><sec id="jvim70006-sec-0009"><label>2.1</label><title>Selection of Cases</title><p>The medical records of all cats undergoing SUB placement for the treatment of BUOs by the authors (Allyson Berent or Chick Weisse, or both) between January 2012 to July 2020 treated at the Animal Medical Center, New York, New York, were retrospectively reviewed. Diagnosis of a ureteral obstruction was generally made based on a combination of imaging findings detected on abdominal ultrasonography (renal pelvic dilation with associated hydroureter usually caused by a nonmalignant obstructive ureteral lesion), abdominal radiographs, and an antegrade ureteropyelography performed at the time of SUB placement using fluoroscopic guidance. Preoperative diagnostic imaging, preoperative serum biochemistry, and a complete surgery report were needed for inclusion with a follow&#x02010;up time of &#x0003e;&#x02009;180&#x02009;days for each cat. Cats were excluded if &#x0003c;&#x02009;180&#x02009;days of follow&#x02010;up data was available for review and &#x0003e;&#x02009;180&#x02009;days lapsed between SUB flushing during the follow&#x02010;up period. If mineralization or a UTI occurred before the first 180&#x02009;days but the follow&#x02010;up time was &#x0003c;&#x02009;180&#x02009;days, these cats were included. Cats and the SUB(s) were grouped based on the material used in their routine SUB flushing procedure. UTI was defined as a positive urine culture and sensitivity (UCS) with associated pyuria and clinical signs including dysuria, nonspecific lethargy, hyporexia, change in behavior, or progressive azotemia. If these criteria were not met, but the urine culture was positive the cat was classified as having asymptomatic bacteriuria (ABU). Chronic UTI was defined as having more than two episodes of UTI in the preceding 12 months or two or more episodes in the preceding 6 months [<xref rid="jvim70006-bib-0020" ref-type="bibr">20</xref>]. Cats were considered to have successfully cleared an infection if a negative UCS was obtained while not receiving medical treatment for infection without recurrence for &#x0003e;&#x02009;6 months. Postoperative sterile dysuria was defined as the development of any lower urinary tract signs in the absence of a positive UCS.</p><p>Group 1 included devices flushed with sterile saline only (devices placed from 4/2012 to 4/2017), Group 2 included devices initially flushed with sterile saline and then switched to 2% tEDTA (devices placed from 5/2012 to 4/2017), and Group 3 included devices only flushed with tEDTA (devices placed from 5/2017 to 7/2021). Data on all cats enrolled was collected until September 2024.</p></sec><sec id="jvim70006-sec-0010"><label>2.2</label><title>Preoperative Data and Management</title><p>Data regarding signalment, history, presenting complaint, imaging findings, and laboratory results were reviewed.</p><p>The cats were medically managed for variable lengths of time before SUB placement depending on clinical status. Medical management included intravenous fluid therapy, alpha&#x02010;adrenergic blockade, antibiotics, H2&#x02010;receptor antagonists or proton pump inhibitors, and antiemetics; specific drug choices and doses were clinician&#x02010;dependent. The cats were monitored by physical exam, hydration assessment, serial ultrasonography, and renal variables.</p></sec><sec id="jvim70006-sec-0011"><label>2.3</label><title>Imaging</title><p>Generally, all cats underwent an abdominal ultrasonography (at a minimum focused on the urinary tract) and abdominal radiographs before surgery.</p><p>Fluoroscopic anterograde ureteropyelography was performed by laparotomy to confirm the ureteral obstruction in each renal/ureteral unit before SUB placement. This was generally performed using an 18&#x02010;gauge over&#x02010;the&#x02010;needle catheter and a 50% mixture of saline and iodinated contrast material [<xref rid="jvim70006-bib-0001" ref-type="bibr">1</xref>]. When possible, urine was collected at the time of pyelocentesis for a urine bacterial culture.</p></sec><sec id="jvim70006-sec-0012"><label>2.4</label><title>
<styled-content style="fixed-case" toggle="no">SUB</styled-content> Device Placement</title><p>The SUB was placed routinely as previously reported and further defined in the SUB instruction for use manual [<xref rid="jvim70006-bib-0001" ref-type="bibr">1</xref>, <xref rid="jvim70006-bib-0021" ref-type="bibr">21</xref>].<xref rid="jvim70006-note-0005" ref-type="fn">
<sup>3</sup>
</xref> For the SUB 2.0 (Figure&#x000a0;<xref rid="jvim70006-supitem-0001" ref-type="supplementary-material">S2a</xref>), both the nephrostomy and cystostomy catheters were passed through the body wall, paramedian to the abdominal incision on the ipsilateral side of the affected kidney, and connected to a shunting port. For the SUB 3.0, the nephrostomy and cystostomy catheters were connected to either a Y&#x02010;connector, if the SUB was unilateral or an X&#x02010;connector if bilateral (Figure&#x000a0;<xref rid="jvim70006-supitem-0001" ref-type="supplementary-material">S2b,c</xref>). In some cases, bilateral obstructions had a unilateral 2.0 and 3.0 device, and in other cases a bilateral obstruction had two Y&#x02010;connectors with two separate SUB 2.0 or 3.0 systems. This decision was clinician dependent.</p></sec><sec id="jvim70006-sec-0013"><label>2.5</label><title>Perioperative Data and Management</title><p>The cats were monitored for hydration using a combination of physical examination, serial bodyweight measurements, and point&#x02010;of&#x02010;care bloodwork. Antibiotic therapy (marbofloxacin ~2.75&#x02009;mg/kg once daily PO via esophagostomy tube) was initiated to prevent the formation of biofilm on the internalized device for 2&#x02009;weeks unless the cat was receiving another antibiotic for a known UTI [<xref rid="jvim70006-bib-0022" ref-type="bibr">22</xref>]. If a positive culture was obtained, an appropriate antibiotic was given for ~6&#x02009;weeks. Electrolytes, BUN, creatinine, packed cell volume/total solids (PCV/TS) were recorded postoperatively and then at least every 24&#x02009;h after surgery until discharge. The SUB was flushed before discharge.</p><p>For each SUB flush (routinely done without sedation), the cat was placed in dorsal recumbency and the port site on the ventral abdomen was clipped of fur and aseptically prepared as defined in the instruction for use manual (Figure&#x000a0;<xref rid="jvim70006-supitem-0001" ref-type="supplementary-material">S1</xref>).<xref rid="jvim70006-note-0006" ref-type="fn">
<sup>4</sup>
</xref> Ultrasonography was used to measure the renal pelvic/ureteral diameter, evaluate the lumen of the urinary bladder and entry site of the cystostomy catheter, and assess the catheter tubing for shadowing or mineralization. A sterile 22G Huber needle connected to a T&#x02010;port and three&#x02010;way stopcock were used to obtain a sterile urine sample from the port. For SUB version 3.0, a 0.5&#x02009;mL presample was removed and discarded before obtaining a sample for culture, as the accessory line could have stagnant tEDTA solution from the prior flush. Sterile saline was then infused using ultrasound&#x02010;guidance in 0.25&#x02013;0.5&#x02009;mL increments and removed after each infusion, while the renal pelvis and the urinary bladder were monitored serially with ultrasonography for turbulence of fluid to confirm device patency. Once patency was established, 2&#x02009;mL of 2% tEDTA was slowly infused in 0.25&#x02009;mL increments as the renal pelvis was carefully visualized with ultrasonography to avoid overdistension.</p></sec><sec id="jvim70006-sec-0014"><label>2.6</label><title>Follow&#x02010;Up</title><p>Typically, evaluation of renal variables, urinalysis/UCS, and a urinary ultrasonography was performed 4&#x02009;weeks postoperatively, and then every 3 months for the first 2&#x02009;years, and every 6 months thereafter. Flush interval was calculated as the average number of days between flushes for each device.</p><p>Mineralization was defined as any occurrence where the device had ultrasonographic shadowing debris appreciated on the catheter(s), while the catheters were flowing and draining. In addition, mineralization was presumptively diagnosed if there were any delay in the visualization of turbulence during the SUB flush, even if flow was documented, if there was an absence of other causes or poor flushing (e.g., kink, blood clot, purulent debris). Complete occlusion was characterized when one or more catheters were unable to be flushed. Exchange was recommended if there was occlusion of any part of the device with associated renal pelvic/ureteral dilation supporting recurrent obstruction. If there was occlusion of the device without evidence of progressive renal pelvic/ureteral dilation, the renal collection system was assumed to be patent, likely associated with resolution of a previous obstruction in the ureteral lumen. In these cases, exchange of the device was not recommended.</p></sec><sec id="jvim70006-sec-0015"><label>2.7</label><title>Statistical Analysis</title><p>Descriptive statistics are presented as means and a standard deviation. Mean differences were carried out by ANOVA. Regression analyses were carried out using OLS for continuous response variables while discrete response variables were analyzed using logistic regression. Frequency analyses were carried out using a Pearson's chi&#x02010;square or Fisher's exact test for cell counts less than five. All analyses were carried out using SAS 9.4 (Cary, NC 2016).</p></sec></sec><sec sec-type="results" id="jvim70006-sec-0016"><label>3</label><title>Results</title><sec id="jvim70006-sec-0017"><label>3.1</label><title>Selection of Cases (Table&#x000a0;<xref rid="jvim70006-tbl-0001" ref-type="table">1</xref>)</title><table-wrap position="float" id="jvim70006-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Cats and devices organized by Group: Number of cats and devices in each group based on laterality, follow&#x02010;up times, and comparisons of median follow&#x02010;up times between groups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Cats</th><th align="center" valign="bottom" rowspan="1" colspan="1">Devices</th><th align="center" valign="bottom" rowspan="1" colspan="1">Unilateral</th><th align="center" valign="bottom" rowspan="1" colspan="1">Bilateral</th><th align="center" valign="bottom" rowspan="1" colspan="1">Median follow&#x02010;up time (mean, range) in days</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Group 1</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;21</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;28</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;14</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;7</td><td align="center" valign="top" rowspan="1" colspan="1">772 (751.5, 194&#x02013;1345)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(compared to Group 2)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.340</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Group 2</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;12</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;16</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;8</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;4</td><td align="center" valign="top" rowspan="1" colspan="1">934.5 (978.4, 335&#x02013;2367)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(compared to Group 3)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.572</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Group 3</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;33</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;51</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;17</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;17</td><td align="center" valign="top" rowspan="1" colspan="1">1015.5 (1067.5, 183&#x02013;2393)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">(SUB 2.0: 17 cats)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(compared to Group 1)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">(SUB 3.0: 16 cats)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.346</td></tr></tbody></table></table-wrap><p>Records for 349 devices in 254 cats were reviewed between 2012 and 2020. Ninety&#x02010;five devices (39 unilateral, 28 bilateral) in 66 cats met the inclusion criteria with 28 devices (14 unilateral, 7 bilateral) in 21 cats in Group 1, 16 (8 unilateral, 4 bilateral) in 12 cats in Group 2, and 51 (17 unilateral, 17 bilateral) in 33 cats in Group 3.</p></sec><sec id="jvim70006-sec-0018"><label>3.2</label><title>Historical and Presenting Clinical Data</title><p>Median age at the time of the procedure was 10.9&#x02009;years (range: 0.6&#x02013;17.2). Age was significantly different between Groups 1 and 2 (mean: 13.2 and 10, respectively; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0013), and between Groups 1 and 3 (mean: 8.6; <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001). There was no significant difference in age between Group 2 and 3 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.21). Forty of 66 (61%) cats had a history of azotemia and were suspected to have CKD based on small kidney size, a history of polyuria and polydipsia, a loss of corticomedullary definition on ultrasonography, or a combination; there was no significant difference between groups. Eight of 66 (12%) cats had previously undergone cystotomy for removal of cystic calculi and there was no significant difference between groups. Nine of 66 (14%) cats had a history of previous UTI before SUB placement and there was no significant difference between Groups 1 and 2 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.26), 1 and 3 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.24), and 2 and 3 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.29). Three of 66 (5%) cats experienced pre&#x02010;procedure dysuria; in two cats this was thought to be idiopathic cystitis and in the third it was secondary to a urethral stone.</p></sec><sec id="jvim70006-sec-0019"><label>3.3</label><title>Clinicopathologic and Laboratory Data</title><p>Overall, the median creatinine at time of surgery was 8.35&#x02009;mg/dL (range: 1.3&#x02013;24.8; reference: 0.9&#x02013;2.3). Median creatinine was 8.2&#x02009;mg/dL (mean: 9.2, range: 1.7&#x02013;23) for Group 1, 7.7&#x02009;mg/dL (mean: 7.8, range: 1.7&#x02013;17.6) for Group 2, and 8.7&#x02009;mg/dL (mean: 9.5, range: 1.3&#x02013;24.8) for Group 3. There was no significant difference in creatinine between groups.</p><p>Overall, the median ionized calcium at time of surgery was 1.05&#x02009;mmol/dL (range: 0.75&#x02013;1.68, reference: 1.20&#x02013;1.32). Sixteen of 18 (88%) cats in Group 1, 12/12 (100%) cats in Group 2, and 28/30 (93%) cats in Group 3 had a normal ionized calcium before surgery; 1 cat in Group 1 had a low ionized calcium and 3 cats (1, Group 1; 2, Group 3) had an elevated ionized calcium before surgery. There was no significant difference in incidence of preoperative hypocalcemia, normocalcemia, or hypercalcemia between groups.</p><p>Seven of 66 (11%) cats (3/21 [14%] in Group 1, 1/12 [8%] in Group 2, 3/33 [9%] in Group 3) had a positive urine culture at the time of surgery. There was no significant difference between the groups. Forty&#x02010;two of 66 (67%) cats had a UCS performed from a sample obtained via pyelocentesis. Four of 42 (10%) cats (1/13 [8%] in Group 1, 1/5 [20%] in Group 2, 2/24 [8%] in Group 3) had a positive UCS from the pelvis. There was no significant difference in a positive culture obtained via pyelocentesis between groups. In two cats, culture obtained via cystocentesis was positive while the culture obtained via pyelocentesis was negative. No cats that had a negative culture via cystocentesis had a positive culture via pyelocentesis. Of the seven cats with positive urine cultures, all were on antibiotic therapy for at least 72&#x02010;h before to surgery. There was no significant difference in preoperative antibiotic therapy between groups.</p></sec><sec id="jvim70006-sec-0020"><label>3.4</label><title>Diagnostic Imaging</title><p>The median preoperative renal pelvic diameter measurements obtained with ultrasonography in a transverse plane was 9&#x02009;mm (range: 1&#x02013;35&#x02009;mm). Renal pelvic diameter was significantly different (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.016) between Groups 2 (mean: 12.2&#x02009;mm) and 3 (mean: 7.8&#x02009;mm), but not significantly different between Groups 1 (mean: 9.9&#x02009;mm) and 2 or 3.</p><p>The etiology for obstruction included ureterolithiasis (74/95; 78%), presumed stricture (21/95; 22%), and purulent debris associated with pyonephrosis (6/95; 6%). Eleven of 74 (15%) ureterolith cases were suspected to be obstructed with dried solidified blood stones based on gross appearance of the stones intraoperatively and 3/74 ureters had concurrent strictures, totaling 24/95 (25%) cats with presumed strictures in this study. There was no significant difference between groups for incidence of ureterolithiasis, stricture, or purulent debris.</p></sec><sec id="jvim70006-sec-0021"><label>3.5</label><title>
<styled-content style="fixed-case" toggle="no">SUB</styled-content> Placement Procedure</title><p>SUBs were successfully placed in all cases. For 79/95 (83%) obstructed ureters SUB 2.0 devices were placed and for 16/95 (17%) obstructed ureters SUB 3.0 devices were placed. All SUB 3.0s were in Group 3. Two SUB 2.0s in Group 3 were exchanged for a SUB 3.0 at 103 and 2113&#x02009;days, respectively, following the initial surgery for complete occlusion secondary to mineralization.</p><p>An intraoperative cystotomy was performed in 14/66 (21%) of cats for concurrent cystolithiasis; there was no significant difference between groups for the need for a cystotomy. Five cats in Group 1, but no cats in Group 2 or 3 had an indwelling urinary catheter placed postoperatively to monitor urine output.</p></sec><sec id="jvim70006-sec-0022"><label>3.6</label><title>Follow&#x02010;Up (Table&#x000a0;<xref rid="jvim70006-tbl-0001" ref-type="table">1</xref>)</title><p>The median survival time was 772&#x02009;days (range: 194&#x02013;1345; mean: 751.5) for Group 1, and 934.5&#x02009;days (range: 355&#x02013;2367; mean: 978.4) for Group 2 with all cats documented dead at the time of writing this manuscript. There was no significant difference between groups. In Group 3, 55% of cats were alive at the time of writing this manuscript, therefore, median survival times could not be calculated, but the median follow&#x02010;up time was 1015.5&#x02009;days (range: 183&#x02013;2393; mean: 1067.5), which was not statistically different than the MST of Groups 1 or 2. No cats in this study were lost to follow&#x02010;up. There was no significant difference in follow&#x02010;up time between groups.</p></sec><sec id="jvim70006-sec-0023"><label>3.7</label><title>Renal Variables (Table&#x000a0;<xref rid="jvim70006-tbl-0002" ref-type="table">2</xref>)</title><table-wrap position="float" id="jvim70006-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Follow&#x02010;up and Group comparisions of creatinine concentrations of cats after SUB placement.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">1 month</th><th align="center" valign="bottom" rowspan="1" colspan="1">3 months</th><th align="center" valign="bottom" rowspan="1" colspan="1">6 months</th><th align="center" valign="bottom" rowspan="1" colspan="1">9 months</th><th align="center" valign="bottom" rowspan="1" colspan="1">12 months</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Group 1, <italic toggle="yes">n</italic>&#x02009;=&#x02009;21</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;21</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;19</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;19</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;15</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;15</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mean (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">2.9</td><td align="center" valign="top" rowspan="1" colspan="1">2.85</td><td align="center" valign="top" rowspan="1" colspan="1">3.24</td><td align="center" valign="top" rowspan="1" colspan="1">3.3</td><td align="center" valign="top" rowspan="1" colspan="1">3.8</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Range</td><td align="center" valign="top" rowspan="1" colspan="1">1.5&#x02013;5.1</td><td align="center" valign="top" rowspan="1" colspan="1">1.4&#x02013;4.8</td><td align="center" valign="top" rowspan="1" colspan="1">1.3&#x02013;5.5</td><td align="center" valign="top" rowspan="1" colspan="1">1.6&#x02013;6.1</td><td align="center" valign="top" rowspan="1" colspan="1">1.5&#x02013;10.3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">(compared to Group 2)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.836</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.096</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.351</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.466</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.07</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Group 2, <italic toggle="yes">n</italic>&#x02009;=&#x02009;12</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;12</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;12</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;9</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;9</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;11</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mean (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">3.0</td><td align="center" valign="top" rowspan="1" colspan="1">2.3</td><td align="center" valign="top" rowspan="1" colspan="1">2.8</td><td align="center" valign="top" rowspan="1" colspan="1">2.9</td><td align="center" valign="top" rowspan="1" colspan="1">2.6</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Range</td><td align="center" valign="top" rowspan="1" colspan="1">1.5&#x02013;10.8</td><td align="center" valign="top" rowspan="1" colspan="1">1.4&#x02013;4.1</td><td align="center" valign="top" rowspan="1" colspan="1">1.2&#x02013;4.3</td><td align="center" valign="top" rowspan="1" colspan="1">1.3&#x02013;5</td><td align="center" valign="top" rowspan="1" colspan="1">1.4&#x02013;5.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">(compared to Group 3)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.785</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.091</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.966</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.608</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.877</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Group 3, <italic toggle="yes">n</italic>&#x02009;=&#x02009;33</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;32</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;33</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;31</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;27</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;27</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mean (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">2.8</td><td align="center" valign="top" rowspan="1" colspan="1">2.9</td><td align="center" valign="top" rowspan="1" colspan="1">2.8</td><td align="center" valign="top" rowspan="1" colspan="1">2.6</td><td align="center" valign="top" rowspan="1" colspan="1">2.5</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Range</td><td align="center" valign="top" rowspan="1" colspan="1">0.9&#x02013;7.4</td><td align="center" valign="top" rowspan="1" colspan="1">1.1&#x02013;7.3</td><td align="center" valign="top" rowspan="1" colspan="1">1.1&#x02013;7</td><td align="center" valign="top" rowspan="1" colspan="1">1.2&#x02013;6.7</td><td align="center" valign="top" rowspan="1" colspan="1">1.3&#x02013;3.9</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">(compared to Group 1)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.876</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.813</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.287</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.082</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;<bold>0.042</bold>
</td></tr></tbody></table><table-wrap-foot id="jvim70006-ntgp-0101"><fn id="jvim70006-note-0102"><p>
<italic toggle="yes">Note:</italic> Bolding of data&#x02009;=&#x02009;significant difference with <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></fn></table-wrap-foot></table-wrap><p>Creatinine concentrations at 1, 3, 6, 9, and 12 months postoperatively were compared and are shown in Table&#x000a0;<xref rid="jvim70006-tbl-0002" ref-type="table">2</xref>. At 1, 3, 6, and 9&#x02010;month postoperatively there was no significant difference in creatinine between Groups 1, 2, and 3. At 12 months postoperatively, mean creatinine was 3.8&#x02009;mg/dL (range: 1.5&#x02013;10.3) for Group 1 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;15), 2.6&#x02009;mg/dL (range: 1.4&#x02013;5.2) for Group 2 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;10), and 2.5&#x02009;mg/dL (range: 1.3&#x02013;3.9) for Group 3 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;27). There was a significant difference at 12 months between Groups 1 and 3 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.042), but not between Groups 1 and 2 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.07) or Groups 2 and 3 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.877).</p></sec><sec id="jvim70006-sec-0024"><label>3.8</label><title>Mineralization (Tables&#x000a0;<xref rid="jvim70006-tbl-0003" ref-type="table">3</xref> and <xref rid="jvim70006-tbl-0004" ref-type="table">4</xref>)</title><table-wrap position="float" id="jvim70006-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Group comparisons&#x000a0;of device mineralization, occlusion, and need for device exchange.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Mineralization</th><th align="center" valign="bottom" rowspan="1" colspan="1">Occlusion</th><th align="center" valign="bottom" rowspan="1" colspan="1">Exchange</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Group 1</td><td align="center" valign="top" rowspan="1" colspan="1">9/28</td><td align="center" valign="top" rowspan="1" colspan="1">8/28</td><td align="center" valign="top" rowspan="1" colspan="1">4/28</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">32%</td><td align="center" valign="top" rowspan="1" colspan="1">29%</td><td align="center" valign="top" rowspan="1" colspan="1">14%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(compared to Group 2)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.337</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.738</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.250</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Group 2</td><td align="center" valign="top" rowspan="1" colspan="1">8/16</td><td align="center" valign="top" rowspan="1" colspan="1">6/16</td><td align="center" valign="top" rowspan="1" colspan="1">5/16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">50%</td><td align="center" valign="top" rowspan="1" colspan="1">38%</td><td align="center" valign="top" rowspan="1" colspan="1">31%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(compared to Group 3)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;<bold>0.025</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.065</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;<bold>0.016</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Group 3</td><td align="center" valign="top" rowspan="1" colspan="1">10/51</td><td align="center" valign="top" rowspan="1" colspan="1">7/51</td><td align="center" valign="top" rowspan="1" colspan="1">3/51</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">19%</td><td align="center" valign="top" rowspan="1" colspan="1">14%</td><td align="center" valign="top" rowspan="1" colspan="1">6%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>(compared to Group 1)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.273</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.137</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.237</td></tr></tbody></table><table-wrap-foot id="jvim70006-ntgp-0002"><fn id="jvim70006-note-0002"><p>
<italic toggle="yes">Note:</italic> Bolded <italic toggle="yes">p</italic>&#x02010;values are considered statistically significant.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jvim70006-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Group comparisons of median time to mineralization occlusion and first UTI.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Occlusion</th><th align="center" valign="bottom" rowspan="1" colspan="1">1st UTI</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Group 1</td><td align="center" valign="top" rowspan="1" colspan="1">8/28 devices (29%)</td><td align="center" valign="top" rowspan="1" colspan="1">6/21 cats (29%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median (days)</td><td align="center" valign="top" rowspan="1" colspan="1">438.5</td><td align="center" valign="top" rowspan="1" colspan="1">104</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mean (days)</td><td align="center" valign="top" rowspan="1" colspan="1">521</td><td align="center" valign="top" rowspan="1" colspan="1">235.7</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Range (days)</td><td align="center" valign="top" rowspan="1" colspan="1">320&#x02013;793</td><td align="center" valign="top" rowspan="1" colspan="1">6&#x02013;1009</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">(compared to Group 2)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.523</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.360</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Group 2</td><td align="center" valign="top" rowspan="1" colspan="1">7/16 devices (38%)</td><td align="center" valign="top" rowspan="1" colspan="1">5/12 cats (42%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median (days)</td><td align="center" valign="top" rowspan="1" colspan="1">455</td><td align="center" valign="top" rowspan="1" colspan="1">251</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mean (days)</td><td align="center" valign="top" rowspan="1" colspan="1">472</td><td align="center" valign="top" rowspan="1" colspan="1">358</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Range (days)</td><td align="center" valign="top" rowspan="1" colspan="1">238&#x02013;1073</td><td align="center" valign="top" rowspan="1" colspan="1">6&#x02013;963</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">(compared to Group 3)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.701</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Group 3</td><td align="center" valign="top" rowspan="1" colspan="1">7/51 devices (14%)</td><td align="center" valign="top" rowspan="1" colspan="1">5/33 cats (15%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median (days)</td><td align="center" valign="top" rowspan="1" colspan="1">480</td><td align="center" valign="top" rowspan="1" colspan="1">222</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mean (days)</td><td align="center" valign="top" rowspan="1" colspan="1">588</td><td align="center" valign="top" rowspan="1" colspan="1">316</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Range (days)</td><td align="center" valign="top" rowspan="1" colspan="1">70&#x02013;2113</td><td align="center" valign="top" rowspan="1" colspan="1">8&#x02013;635</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">(compared to Group 1)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.772</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.523</td></tr></tbody></table></table-wrap><p>Evidence of mineralization of the device on ultrasound occurred in 9/28 (32%), 8/16 (50%), and 10/51 (19%) in Groups 1, 2, and 3, respectively. There was a significant difference between Groups 2 and 3 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.025). Complete occlusion of the SUB from mineralization occurred in 8/28 (29%), 6/16 (38%), and 7/51 (14%) devices in Groups 1, 2, and 3, respectively, with no significant difference between groups. Device exchange was needed in 4/28 (14%), 5/16 (31%), and 3/51 (6%) devices in Groups 1, 2, and 3, respectively. There was a significant difference between Groups 2 and 3 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.016), but not between Groups 1 and 2 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.25) or Groups 1 and 3 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.24). In two of four (50%) Group 1 device exchanges and four of five (80%) Group 2 device exchanges, more than one device exchange was needed due to recurrence of complete occlusion from mineralization. None of the exchanged devices in Group 3 were exchanged more than once at the time of last follow&#x02010;up. Of the 17 SUB 3.0 devices in Group 3 there was no significant difference in rate of mineralization compared to SUB 2.0 devices in Group 3 but a majority of the devices were the 2.0 version.</p><p>The median time to complete occlusion (Table&#x000a0;<xref rid="jvim70006-tbl-0004" ref-type="table">4</xref>) from mineralization was 438.5&#x02009;days (range: 320&#x02013;793; mean: 521) for Group 1, 455&#x02009;days (range: 238&#x02013;1073; mean: 472) for Group 2, and 480&#x02009;days (range: 70&#x02013;2113; mean: 588) for Group 3. There was no significant difference between groups for time to mineralization occlusion.</p><p>When the cause of obstruction was considered, cats with ureterolithiasis as a cause had a&#x000a0;median time to mineralization occlusion of 488&#x02009;days (range: 238&#x02013;1073; mean: 531.1), while those with non&#x02010;ureteroliths as a cause were 339&#x02009;days (range: 238&#x02013;541; mean: 364.5) (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.16). There was no significant association between those with ureterolithasis and mineralization (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.33), time to mineralization (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.25), complete occlusion from mineralization (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.99), or need for SUB exchange (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.19).</p><p>Postoperative hypercalcemia was documented in 3/21 (14%), 2/12 (16%), and 5/33 (15%) of cats in Groups 1, 2, and 3, respectively; there was no significant difference between groups. There was no association between postoperative hypercalcemia and mineralization (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.08), time to documentation of mineralization (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.16), complete occlusion from mineralization (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.37), time to complete occlusion from mineralization (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.37), and need for SUB exchange from mineralization (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.08), though it was approaching significance at <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.08 for an association of hypercalcemia and mineralization. Of the 10 cats that had documentation of hypercalcemia, 7/10 cats were medically managed for idiopathic hypercalcemia (based on PTH profile), given medications to try and minimize calciuria, or both. Therefore, these cats were managed for their hypercalcemia during the follow&#x02010;up period. Treatment generally consisted of alendronate (10&#x02009;mg/week) and oral hydrochlorothiazide (~1&#x02009;mg/kg q12h PO), potassium citrate (100&#x02013;150&#x02009;mg/kg/day PO), or both. Follow&#x02010;up ionized calcium levels were not available for review in all cats to report medical success.</p></sec><sec id="jvim70006-sec-0025"><label>3.9</label><title>Infection (Tables&#x000a0;<xref rid="jvim70006-tbl-0004" ref-type="table">4</xref> and <xref rid="jvim70006-tbl-0005" ref-type="table">5</xref>)</title><table-wrap position="float" id="jvim70006-tbl-0005" content-type="TABLE"><label>TABLE 5</label><caption><p>Group comparisons of data on cats for infection by group.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Any bacteriuria</th><th align="center" valign="bottom" rowspan="1" colspan="1">Chronic UTI</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cleared infection</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Group 1</td><td align="center" valign="top" rowspan="1" colspan="1">7/21</td><td align="center" valign="top" rowspan="1" colspan="1">7/21</td><td align="center" valign="top" rowspan="1" colspan="1">0/7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">33%</td><td align="center" valign="top" rowspan="1" colspan="1">33%</td><td align="center" valign="top" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">(compared to Group 2</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.347</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;1.000</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.192</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(compared to Group 2</td><td align="center" valign="top" rowspan="1" colspan="1">6/12</td><td align="center" valign="top" rowspan="1" colspan="1">4/12</td><td align="center" valign="top" rowspan="1" colspan="1">2/6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">50%</td><td align="center" valign="top" rowspan="1" colspan="1">33%</td><td align="center" valign="top" rowspan="1" colspan="1">33%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Group 3</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.147</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;<bold>0.014</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.091</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Group 3</td><td align="center" valign="top" rowspan="1" colspan="1">8/33</td><td align="center" valign="top" rowspan="1" colspan="1">1/33</td><td align="center" valign="top" rowspan="1" colspan="1">7/8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">24%</td><td align="center" valign="top" rowspan="1" colspan="1">3%</td><td align="center" valign="top" rowspan="1" colspan="1">88%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">(compared to Group 1)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.541</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;<bold>0.004</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;<bold>0.001</bold>
</td></tr></tbody></table><table-wrap-foot id="jvim70006-ntgp-0102"><fn id="jvim70006-note-0103"><p>
<italic toggle="yes">Note:</italic> Bolding of data&#x02009;=&#x02009;significant difference with <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></fn></table-wrap-foot></table-wrap><p>Documentation of any postoperative bacteriuria occurred in 7/21 (33%), 6/12 (50%), and 8/33 (24%) of cats in Groups 1, 2, and 3, respectively, which were not statistically different. Chronic UTI, as defined above, was associated with clinical UTIs and occurred in 7/21 (33%), 4/12 (33%), and 1/33 (3%) cats in Groups 1, 2, and 3, respectively. There was a significant difference between Groups 1 and 3 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.004) and Groups 2 and 3 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.014), but not between Groups 1 and 2 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;1.0). Four of 12 cats (33%) with chronic UTIs (1/7 Group 1, 2/4 Group 2, and 1/1 Group 3) were actively infected at the time of surgery. Seven of 12 cats (58%) with chronic UTI (3/7 [43%] Group 1, 3/4 [75%] Group 2, and 1/1 [100%] Group 3) had a history of chronic infections before SUB placement.</p><p>UTI at the time of surgery was significantly (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.01) associated with the development of a chronic UTI. Infections were cleared in zero of seven (0%), two of six (33%), and seven of eight (88%) cats in Groups 1, 2, and 3, respectively, in cats that had one or more UTIs throughout the study. There was a significant difference between Groups 1 and 3 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.001). The median time to first UTI was 104&#x02009;days (range: 6&#x02013;1009; mean: 235.7) for Group 1, 251&#x02009;days (range: 6&#x02013;963; mean: 358) for Group 2, and 222&#x02009;days (range: 8&#x02013;635; mean: 316) for Group 3 and no group was statistically different.</p></sec><sec id="jvim70006-sec-0026"><label>3.10</label><title>Dysuria</title><p>Four of 66 (6%) cats had postoperative dysuria (1, Group 2; 3 Group 3). Three of the four cats had preoperative dysuria. Two of these three cats had idiopathic cystitis and continued to have intermittent episodes of dysuria postoperatively. One of the cats with preoperative dysuria had a urethral stone preoperatively and developed postoperative dysuria with a fibrous band of tissue that formed around the bladder body distorting the shape; the dysuria resolved following removal of that band and the cystostomy catheter. This cat had resolution of the ureteral obstruction based on ureterogram and the SUB was removed from the cats urinary bladder at the time of the second surgery. The remaining cat with a newly developed postoperative dysuria was thought to have idiopathic cystitis given the lack of temporal association with tEDTA infusion, absence of bacteriuria, the intermittent signs associated with stress, and the self&#x02010;limiting nature. There was not a significant difference in the incidence of dysuria in cats that received a SUB 3.0 or 2.0 device in Group 3.</p></sec></sec><sec sec-type="discussion" id="jvim70006-sec-0027"><label>4</label><title>Discussion</title><p>The goal of this study was not to compare SUB 2.0 and 3.0 devices and that work is ongoing by the authors. The results of this study suggest that the prophylactic use of tEDTA might be helpful in decreasing SUB mineralization rates and postoperative bacteriuria and associated UTIs, without reducing postoperative renal function or causing dysuria. There were fewer cats in this study that received a SUB 3.0 device compared to a 2.0, but there was no detectible increase in complications based on device model and the rate of complications in this study. Aside from the mean and median age of cats in Groups 1 and 3 being significantly different, over half of the cats in Group 3 were still alive at the time of data collection. The median survival/follow&#x02010;up times were not significantly different for Group 3 cats (1116&#x02009;days), compared to Groups 1 (772&#x02009;days) and 2 (934&#x02009;days), supporting the duration of the time the implant was indwelling was comparable between groups.</p><p>SUB device mineralization, occlusion from mineralization, or the need for device exchange occurred less often in Group 3 devices (19%, 14%, 6%, respectively) compared to Group 1 (32%, 29%, 14%, respectively) or Group 2 devices (50%, 38%, 31%, respectively). The rate between Groups 2 and 3 were statistically different for mineralization (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.025) and exchange (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.016).</p><p>No group had a statistically different mean or median time to first occlusion, but Group 3, which had the longest mean and median follow&#x02010;up time overall, had a longer mean time to mineralization occlusion, and had less occlusions reported overall (29%, 38%, and 14% in Groups 1, 2, and 3, respectively). Additionally, of the devices exchanged, 50% of those in Group 1 and 80% of those in Group 2 required more than one exchange per device, while those in Group 3 only required one. It is important to consider all groups having similar follow&#x02010;up times that go beyond the time of median device mineralization that has been previously reported (463&#x02009;days) to ensure the data is comparable covering a time period where the event is expected to occur.</p><p>The development of postoperative hypercalcemia was also evaluated to assess for a potential confounding factor causing mineralization, but there was no significant difference in incidence between groups despite there being a difference in mineralization rates. One additional factor to consider is that over time the authors' have become more aggressive in the treatment of marginal hypercalcemia with hydrochlorothiazide, potassium citrate, high fiber diets, chia seed intake, and bisphosphonate therapy, when indicated. This could account for the fact that cats that have evidence of hypercalcemia have improvements over time and are on chelators to minimize calcium in the urine. Therefore, they might have less mineralization due to that aggressive therapy. Despite that, a minority of the cats in each group were hypercalcemic.</p><p>Evidence of a chronic UTI occurred less often in Group 3 cats (3%) compared to Group 1 (33%) and Group 2 (33%). Additionally, cats in Group 3 were more often able to clear their bacteriuria long&#x02010;term (88% compared to 0% in Group 1 and 33% in Group&#x000a0;2). There were significant differences between Groups 1 and 3 for incidence of chronic UTI (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.004) and ability to their clear infection (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.001). While there was no significant difference between Groups 1 and 3 for incidence of any bacteriuria developing (33% vs. 24%, respectively) the development of chronic UTIs was statistically significantly less for Group 3&#x000a0;(33% vs. 3%, respectively). These findings suggest that compared to sterile saline, tEDTA might be protective long&#x02010;term against the development of chronic infections and preventative for recurrent infections. In addition, if bacteriuria was documented at the time of surgery based on a positive urine culture, there was a statistical association with that cat developing chronic UTIs in the long&#x02010;term (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.01), which has been documented previously [<xref rid="jvim70006-bib-0001" ref-type="bibr">1</xref>].</p><p>Another interesting finding was that no cat had a positive culture by pyelocentesis without a positive culture by a cystocentesis, whereas two cats had a positive culture by cystocentesis and not by pyelocentesis, supporting that occult pyelonephritis in cats might not be a common occurrence and doing diagnostic pyelocentesis in cats that have a negative urine culture by cystocentesis to screen for pyelonephritis&#x000a0;may not be warranted.</p><p>Renal variables at multiple time points during the follow&#x02010;up period were not significantly different between groups except for creatinine concentrations at 12 months postoperatively between Groups 1 and 3 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.042), where Group 3 had a lower mean creatinine (2.5&#x02009;mg/dL) compared to Group 1 (3.8&#x02009;mg/dL). This suggests that tEDTA infusions do not exacerbate chronic azotemia. The relative differences between Groups 1 and 3 could be due to several factors including greater age in Group 1, improved medical care in recent years, longer follow&#x02010;up times with a larger number of cats followed long&#x02010;term&#x000a0;in Group 3, or improved outcomes due to a decreased incidence of mineralization and infection causing additional renal insult.</p><p>There are several limitations of this study. Many cats that would have been in Group 1 were excluded due to an incomplete medical record or a lack of documentation of routine SUB flushing because at the time of the first SUB placement, routine flushing was not the standard of care and there were no electronic medical records for the authors to capture this data. To consistently compare groups, the authors were careful to ensure that all medical records were complete, at least 180&#x02009;days of follow&#x02010;up time was available, so all groups were comparable to known historical incidence of complications, and the full records were available for review, as well as similar follow&#x02010;up details on each cat. Overall, this limited the number of cats in each group meeting the inclusion criteria. Additionally, the degree of follow&#x02010;up needed to meet inclusion criteria could have created a bias population as perhaps cats that experienced mineralization or UTI had owners that were more likely to seek care and adhere to the recommendations for reevaluation compared to cats that did not experience these issues, or the opposite could be true and those cats that followed a rigorous follow&#x02010;up schedule were more likely to be maintained on quality diets, managing their hypercalemia more aggressively, and more strictly returning&#x000a0;for SUB flush maintenance. Group 2 was a difficult group to analyze because some cats could have spent 3&#x02009;years being flushed with saline and 6 months with tEDTA, and others 3 months with saline and years with tEDTA, pending the year of their surgery. Both circumstances would have fit within the inclusion criteria for Group 2 and not Groups 1 or 3. We felt this group was important to evaluate to see if there was a trend in that group away from Group 1 and toward Group 3 or vice versa. Due to the small numbers this resulted in the data from this group being harder to interpret.</p><p>Additionally, Group 3 cats started having the SUB 3.0 device placed in 2019, toward the end of this collection period. It was hard to determine if any of the differences were due to the 3.0 version of the device compared to the 2.0 version of the device but the data evaluated did not suggest there was a difference. The cats with the 3.0 device had shorter follow&#x02010;up times than those with a 2.0 device, naturally. Finally, Group 3 cats had the longest follow&#x02010;up times compared to the other groups with a majority of cats still being alive. This could have biased the study sample to lead to higher mineralization or infection rates overtime, but instead they had lower rates compared to the two other groups, supporting the hypothesis even further that tEDTA could support decreasing these two long&#x02010;term complications and should be considered in the long&#x02010;term management of these devices. One additional limitation was the failure to include a group of cats over the same long&#x02010;term period of time that did not have any flushing performed. Finally, over the time course of this study medical management for CKD, hypercalcemia and SUB flushing/exchange could have become more aggressive, biasing the two populations between Groups 1 and 3. The protocols for medical management and SUB maintenance over this time period, in the authors' practice, are identical. The only modification was the addition of tEDTA to the flushing regimen, making this potential unlikely to confound the results.</p><p>In conclusion, prophylactic use of 2% tEDTA could be helpful at decreasing mineralization, the need for device exchange, chronic postoperative urinary tract infections, and the ability to clear infections in cats after SUB placement for BUOs. tEDTA did not result in any obvious adverse effects on renal function or the development of dysuria. The authors consider infusion of tEDTA part of their standard&#x02010;of&#x02010;care in managing cats with the SUB device(s) long&#x02010;term.</p></sec><sec id="jvim70006-sec-0029"><title>Disclosure</title><p>Authors declare no off&#x02010;label use of antimicrobials.</p></sec><sec id="jvim70006-sec-0030"><title>Ethics Statement</title><p>Authors declare no Institutional Animal Care and Use Committee (IACUC) or other approval was needed. Authors declare human ethics approval was not needed.</p></sec><sec sec-type="COI-statement" id="jvim70006-sec-0031"><title>Conflicts of Interest</title><p>Drs Berent and Weisse are consultants for Norfolk Vet and Infiniti Medical Vet Products and designed the SUB device.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="jvim70006-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>Data S1.</bold> Supporting Information.</p></caption><media xlink:href="JVIM-39-e70006-s001.pdf"/></supplementary-material></sec></body><back><ack id="jvim70006-sec-0028"><title>Acknowledgments</title><p>Guillermo Mejia is acknowledged for his contributions to surgical preparation and care for the cats included in this study.</p></ack><fn-group id="jvim70006-ntgp-0003"><title>Endnotes</title><fn id="jvim70006-note-0003"><label>
<sup>1</sup>
</label><p>Tetrasodium EDTA, Norfolk Vet Products, Skokie, IL.</p></fn><fn id="jvim70006-note-0004"><label>
<sup>2</sup>
</label><p>SUB device, Norfolk Vet Products, Skokie, IL.</p></fn><fn id="jvim70006-note-0005"><label>
<sup>3</sup>
</label><p>SUB device instruction for use manual (<ext-link xlink:href="https://norfolkvetproducts.com/wp-content/uploads/2020/10/SUB3_Surgical_Guide_2020-09-email.pdf" ext-link-type="uri">https://norfolkvetproducts.com/wp&#x02010;content/uploads/2020/10/SUB3_Surgical_Guide_2020&#x02010;09&#x02010;email.pdf</ext-link>).</p></fn><fn id="jvim70006-note-0006"><label>
<sup>4</sup>
</label><p>SUB flush instruction for use manual (<ext-link xlink:href="https://norfolkvetproducts.com/PDF/SUB/SUB_Flush_Guide_2018-01-email.pdf" ext-link-type="uri">https://norfolkvetproducts.com/PDF/SUB/SUB_Flush_Guide_2018&#x02010;01&#x02010;email.pdf</ext-link>).</p></fn></fn-group><ref-list content-type="cited-references" id="jvim70006-bibl-0001"><title>References</title><ref id="jvim70006-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jvim70006-cit-0001">
<string-name>
<given-names>A. C.</given-names>
<surname>Berent</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Weisse</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Bagley</surname>
</string-name>, and <string-name>
<given-names>K.</given-names>
<surname>Lamb</surname>
</string-name>, &#x0201c;<article-title>The Use of a Subcutaneous Ureteral Bypass (SUB) Device for the Treatment of Ureteral Obstructions in Cats: 137 Cats; 174 Ureters (2009&#x02013;2015)</article-title>,&#x0201d; <source>Journal of the American Veterinary Medical Association</source>
<volume>253</volume> (<year>2018</year>): <fpage>1309</fpage>&#x02013;<lpage>1327</lpage>.<pub-id pub-id-type="pmid">30398425</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jvim70006-cit-0002">
<string-name>
<given-names>E. M.</given-names>
<surname>Butty</surname>
</string-name> and <string-name>
<given-names>M. A.</given-names>
<surname>Labato</surname>
</string-name>, &#x0201c;<article-title>Subcutaneous Ureteral Bypass Device Placement With Intraoperative Ultrasound Guidance, With or Without Microsurgical Ureterotomy, in 24 Cats</article-title>,&#x0201d; <source>Journal of Feline Medicine and Surgery</source>
<volume>23</volume>, no. <issue>12</issue> (<year>2021</year>): <fpage>1183</fpage>&#x02013;<lpage>1191</lpage>.<pub-id pub-id-type="pmid">33754880</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jvim70006-cit-0003">
<string-name>
<given-names>M.</given-names>
<surname>Cray</surname>
</string-name>, <string-name>
<given-names>A. C.</given-names>
<surname>Berent</surname>
</string-name>, <string-name>
<given-names>C. W.</given-names>
<surname>Weisse</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Bagley</surname>
</string-name>, &#x0201c;<article-title>Treatment of Pyonephrosis With a Subcutaneous Ureteral Bypass Device in 4 Cats</article-title>,&#x0201d; <source>Journal of the American Veterinary Medical Association</source>
<volume>252</volume> (<year>2018</year>): <fpage>744</fpage>&#x02013;<lpage>753</lpage>.<pub-id pub-id-type="pmid">29504856</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jvim70006-cit-0004">
<string-name>
<given-names>C.</given-names>
<surname>Horowitz</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Berent</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Weisse</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Langston</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Bagley</surname>
</string-name>, &#x0201c;<article-title>Predictors of Outcome for Cats With Ureteral Obstructions After Interventional Management Using Ureteral Stents or a Subcutaneous Ureteral Bypass Device</article-title>,&#x0201d; <source>Journal of Feline Medicine and Surgery</source>
<volume>15</volume> (<year>2013</year>): <fpage>1052</fpage>&#x02013;<lpage>1062</lpage>.<pub-id pub-id-type="pmid">23723387</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jvim70006-cit-0005">
<string-name>
<given-names>V.</given-names>
<surname>Livet</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Pillard</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Thollot&#x02010;Goy</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Placement of Subcutaneous Ureteral Bypasses Without Fluoroscopic Guidance in Cats With Ureteral Obstruction: 19 Cases (2014&#x02013;2016)</article-title>,&#x0201d; <source>Journal of Feline Medicine and Surgery</source>
<volume>19</volume> (<year>2017</year>): <fpage>1030</fpage>&#x02013;<lpage>1039</lpage>.<pub-id pub-id-type="pmid">27694368</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jvim70006-cit-0006">
<string-name>
<given-names>J. A.</given-names>
<surname>Sapora</surname>
</string-name>, <string-name>
<given-names>R. J.</given-names>
<surname>Hardie</surname>
</string-name>, and <string-name>
<given-names>N.</given-names>
<surname>Evans</surname>
</string-name>, &#x0201c;<article-title>Use of a Subcutaneous Ureteral Bypass Device for Treatment of Bilateral Proximal Ureteral Injury in a 9&#x02010;Month&#x02010;Old Cat</article-title>,&#x0201d; <source>Journal of Feline Medicine and Surgery</source>
<volume>8</volume> (<year>2019</year>): <fpage>420</fpage>&#x02013;<lpage>423</lpage>.</mixed-citation></ref><ref id="jvim70006-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jvim70006-cit-0007">
<string-name>
<given-names>E.</given-names>
<surname>Vrijsen</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Devriendt</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Mortier</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Stock</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Van Goethem</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>de Rooster</surname>
</string-name>, &#x0201c;<article-title>Complications and Survival After Subcutaneous Ureteral Bypass Device Placement in 24 Cats: A Retrospective Study (2016&#x02013;2019)</article-title>,&#x0201d; <source>Journal of Feline Medicine and Surgery</source>
<volume>23</volume>, no. <issue>8</issue> (<year>2021</year>): <fpage>759</fpage>&#x02013;<lpage>769</lpage>.<pub-id pub-id-type="pmid">33231515</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jvim70006-cit-0008">
<string-name>
<given-names>C.</given-names>
<surname>Wormser</surname>
</string-name>, <string-name>
<given-names>D. L.</given-names>
<surname>Clarke</surname>
</string-name>, and <string-name>
<given-names>L. R.</given-names>
<surname>Aronson</surname>
</string-name>, &#x0201c;<article-title>Outcomes of Ureteral Surgery and Ureteral Stenting in Cats: 117 Cases (2006&#x02013;2014)</article-title>,&#x0201d; <source>Journal of the American Veterinary Medical Association</source>
<volume>248</volume>, no. <issue>5</issue> (<year>2016</year>): <fpage>518</fpage>&#x02013;<lpage>525</lpage>.<pub-id pub-id-type="pmid">26885594</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jvim70006-cit-0009">
<string-name>
<given-names>F.</given-names>
<surname>Wuillemin</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Vachon</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Beauchamp</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Dunn</surname>
</string-name>, &#x0201c;<article-title>Subcutaneous Ureteral Bypass Device Placement in 81 Cats With Benign Ureteral Obstruction (2013&#x02013;2018)</article-title>,&#x0201d; <source>Journal of Veterinary Internal Medicine</source>
<volume>35</volume>, no. <issue>6</issue> (<year>2021</year>): <fpage>2778</fpage>&#x02013;<lpage>2786</lpage>.<pub-id pub-id-type="pmid">34894007</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jvim70006-cit-0010">
<string-name>
<given-names>A. C.</given-names>
<surname>Berent</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Weisse</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Bagley</surname>
</string-name>, &#x0201c;<article-title>Technical and Clinical Outcomes of Ureteral Stenting in Cats With Benign Ureteral Obstructions: 69 Cases (2006&#x02013;2010)</article-title>,&#x0201d; <source>Journal of the American Veterinary Medical Association</source>
<volume>244</volume> (<year>2014</year>): <fpage>559</fpage>&#x02013;<lpage>576</lpage>.<pub-id pub-id-type="pmid">24548231</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jvim70006-cit-0011">
<string-name>
<given-names>W. T.</given-names>
<surname>Culp</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Palm</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Hsueh</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Outcome in Cats With Benign Ureteral Obstructions Treated by Means of Ureteral Stenting Versus Ureterotomy</article-title>,&#x0201d; <source>Journal of the American Veterinary Medical Association</source>
<volume>249</volume> (<year>2016</year>): <fpage>1292</fpage>&#x02013;<lpage>1300</lpage>.<pub-id pub-id-type="pmid">27875083</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jvim70006-cit-0012">
<string-name>
<given-names>N. J.</given-names>
<surname>Kulendra</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Syme</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Benigni</surname>
</string-name>, and <string-name>
<given-names>Z.</given-names>
<surname>Halfacree</surname>
</string-name>, &#x0201c;<article-title>Feline Double Pigtail Ureteric Stents for Management of Ureteric Obstruction: Short&#x02010; and Long&#x02010;Term Follow&#x02010;Up of 26 Cats</article-title>,&#x0201d; <source>Journal of Feline Medicine and Surgery</source>
<volume>16</volume> (<year>2014</year>): <fpage>985</fpage>&#x02013;<lpage>991</lpage>.<pub-id pub-id-type="pmid">24782460</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jvim70006-cit-0013">
<string-name>
<given-names>A. E.</given-names>
<surname>Kyles</surname>
</string-name>, <string-name>
<given-names>E. M.</given-names>
<surname>Hardie</surname>
</string-name>, <string-name>
<given-names>B. G.</given-names>
<surname>Wooden</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Management and Outcome of Cats With Ureteral Calculi: 153 Cases (1984&#x02013;2002)</article-title>,&#x0201d; <source>Journal of the American Veterinary Medical Association</source>
<volume>226</volume> (<year>2005</year>): <fpage>937</fpage>&#x02013;<lpage>944</lpage>.<pub-id pub-id-type="pmid">15786997</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jvim70006-cit-0014">
<string-name>
<given-names>S. F.</given-names>
<surname>Roberts</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Aronson</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Brown</surname>
</string-name>, &#x0201c;<article-title>Postoperative Mortality in Cats After Ureterolithotomy</article-title>,&#x0201d; <source>Veterinary Surgery</source>
<volume>40</volume> (<year>2011</year>): <fpage>438</fpage>&#x02013;<lpage>443</lpage>.<pub-id pub-id-type="pmid">21545462</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jvim70006-cit-0015">
<string-name>
<given-names>M. S.</given-names>
<surname>Zaid</surname>
</string-name>, <string-name>
<given-names>A. C.</given-names>
<surname>Berent</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Weisse</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Caceres</surname>
</string-name>, &#x0201c;<article-title>Feline Ureteral Strictures: 10 Cases (2007&#x02013;2009)</article-title>,&#x0201d; <source>Journal of Veterinary Internal Medicine</source>
<volume>25</volume> (<year>2011</year>): <fpage>222</fpage>&#x02013;<lpage>229</lpage>.<pub-id pub-id-type="pmid">21314722</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jvim70006-cit-0016">
<string-name>
<given-names>A.</given-names>
<surname>Timmermann</surname>
</string-name> and <string-name>
<given-names>G.</given-names>
<surname>Kallistratos</surname>
</string-name>, &#x0201c;<article-title>Modern Aspects of Chemical Dissolution of Human Renal Calculi by Irrigation</article-title>,&#x0201d; <source>Journal of Urology</source>
<volume>95</volume> (<year>1966</year>): <fpage>469</fpage>&#x02013;<lpage>475</lpage>.<pub-id pub-id-type="pmid">4956497</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jvim70006-cit-0017">
<string-name>
<given-names>S. L.</given-names>
<surname>Percival</surname>
</string-name>, <string-name>
<given-names>N. A.</given-names>
<surname>Sabbuba</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Kite</surname>
</string-name>, and <string-name>
<given-names>D. J.</given-names>
<surname>Stickler</surname>
</string-name>, &#x0201c;<article-title>The Effect of EDTA Instillation on the Rate of Development of Encrustation and Biofilms in Foley Catheters</article-title>,&#x0201d; <source>Urological Research</source>
<volume>37</volume> (<year>2009</year>): <fpage>205</fpage>&#x02013;<lpage>209</lpage>.<pub-id pub-id-type="pmid">19468723</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jvim70006-cit-0018">
<string-name>
<given-names>C.</given-names>
<surname>Chik</surname>
</string-name>, <string-name>
<given-names>A. C.</given-names>
<surname>Berent</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Weisse</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Therapeutic Use of Tetrasodium Ethylenediaminetetraacetic Acid Solution for Treatment of Subcutaneous Ureteral Bypass Device Mineralization in Cats</article-title>,&#x0201d; <source>Journal of Veterinary Internal Medicine</source>
<volume>35</volume> (<year>2019</year>): <fpage>2124</fpage>&#x02013;<lpage>2132</lpage>.</mixed-citation></ref><ref id="jvim70006-bib-0019"><label>19</label><mixed-citation publication-type="book" id="jvim70006-cit-0019">
<string-name>
<given-names>A.</given-names>
<surname>Berent</surname>
</string-name>, <article-title>SUB Management for the Internist</article-title> (<publisher-loc>Pheonix, AZ</publisher-loc>: <publisher-name>ACVIM</publisher-name>, <year>2019</year>).</mixed-citation></ref><ref id="jvim70006-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jvim70006-cit-0020">
<string-name>
<given-names>A.</given-names>
<surname>Aydin</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Ahmed</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Zaman</surname>
</string-name>, <string-name>
<given-names>M. S.</given-names>
<surname>Khan</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Dasgupta</surname>
</string-name>, &#x0201c;<article-title>Recurrent Urinary Tract Infections in Women</article-title>,&#x0201d; <source>International Urogynecology Journal</source>
<volume>26</volume>, no. <issue>6</issue> (<year>2015</year>): <fpage>795</fpage>&#x02013;<lpage>804</lpage>.<pub-id pub-id-type="pmid">25410372</pub-id>
</mixed-citation></ref><ref id="jvim70006-bib-0021"><label>21</label><mixed-citation publication-type="book" id="jvim70006-cit-0021">
<string-name>
<given-names>A.</given-names>
<surname>Berent</surname>
</string-name> and <string-name>
<given-names>C.</given-names>
<surname>Weisse</surname>
</string-name>, <source>SUB 3.0 A Surgical Guide</source> (<publisher-name>Norfolk Vet Products</publisher-name>, <year>2020</year>).</mixed-citation></ref><ref id="jvim70006-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jvim70006-cit-0022">
<string-name>
<given-names>G.</given-names>
<surname>Reid</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Habash</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Vachon</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Denstedt</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Riddell</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Beheshti</surname>
</string-name>, &#x0201c;<article-title>Oral Fluoroquinolone Therapy Results in Drug Adsorption on Ureteral Stents and Prevention of Biofilm Formation</article-title>,&#x0201d; <source>International Journal of Antimicrobial Agents</source>
<volume>17</volume> (<year>2001</year>): <fpage>317</fpage>&#x02013;<lpage>320</lpage>.<pub-id pub-id-type="pmid">11295415</pub-id>
</mixed-citation></ref></ref-list></back></article>